Pre-existing oral contrast from lanthanum carbonate: a confounding factor in CT mesenteric angiography

• Published in: British journal of radiology 2012-04, Vol.85 (1012), p.e73-e75
• Main Authors: Bull, M D, Shrimanker, R, Thomas, M R M, Mulgrew, C J
• Format: Article
• Language: English
• Subjects: Administration, Oral; Aged; Angiography; Case Report; Contrast Media - administration & dosage; Gastrointestinal Hemorrhage - diagnostic imaging; Humans; Hyperphosphatemia - drug therapy; Lanthanum - administration & dosage; Lanthanum - therapeutic use; Male; Mesenteric Arteries - diagnostic imaging; Tomography, X-Ray Computed
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr/20741726

A 69-year-old male was referred from the renal unit to radiology for investigation of bleeding per rectum. A CT mesenteric angiogram was performed. However, it was noted on the pre-contrast images that the large bowel contained positive oral contrast media. The procedure was abandoned as it would have been difficult to see extravasation of intravenous contrast from a bleeding point in the large bowel. The initial belief was that either the patient had been given oral contrast by ward staff on the assumption that it would be needed, or had had a recent radiological study requiring contrast, which was still present. Neither was the case; it emerged that the patient was taking Fosrenol (Shire Pharmaceuticals, Wayne, PA), a lanthanum carbonate medication used in the treatment of hyperphosphataemia. Lanthanum is densely radio-opaque and appears as positive bowel contrast on CT and plain radiography studies. When considering radiological studies specifically requiring the absence of oral contrast, it is important to be aware of the patient's drug history to avoid non-diagnostic scans with the associated radiation exposure.